PubMed · 13237707
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
P M OSTERRIETH. 1954. [New data on bleeding time].. https://pubmed.ncbi.nlm.nih.gov/13237707/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
BACKGROUND: An Arg60-to-Leu mutation was found in the first cytoplasmic loop of the PLT TxA2 receptor as a new congenital PLT disorder characterized by impaired responsiveness to TxA2. However, it has not been clarified whether DDAVP is effective in correcting the bleeding time (BT) in this PLT disorder. STUDY DESIGN AND METHODS: DDAVP (0.4 microg/kg) was intravenously administered over 20 minutes in five patients with this PLT disorder, and template BT, PLT retention to glass beads, PLT aggregation, and a coagulation study were performed before and after the infusion of DDAVP. PLT TxA2 synthesis defects (cyclo-oxygenase deficiency, volunteers taking aspirin), thrombasthenia, and Bernard-Soulier syndrome were also included in this study. RESULTS: The normalization of BT was found in all patients with this PLT disorder, and one of the patients successfully underwent oral surgical procedures with DDAVP as the only hemostatic agent. DDAVP was also efficacious in the TxA2 synthesis defect but not in other disorders. FVIII coagulation activity, vWF antigen, and ristocetin cofactor significantly increased in all patients after DDAVP, but no changes were seen in the PLT retention rate and PLT aggregation study after DDAVP infusion. CONCLUSION: DDAVP was effective in correcting BT in patients with impaired responsiveness to TxA2 as well as impaired production of TxA2.
Neoplasm-related nephrotic syndrome exhibiting focal segmental glomerulosclerosis (FSGS) has been reported mainly in patients with hematologic malignancies. The association of FSGS with carcinoma is very rare and nephrotic syndrome caused by FSGS has not yet been reported in patients with lung cancer. We report a case of nephrotic syndrome caused by FSGS in a 61-year-old man with advanced non-small-cell lung cancer. In addition, platelet dysfunction evidenced by prolonged bleeding time was noted. The renal problem and prolonged bleeding time resolved dramatically during radiotherapy for lung cancer. We speculate that both FSGS and prolonged bleeding time are paraneoplastic syndromes associated with lung cancer, although the underlying mechanisms of both conditions remain to be elucidated.